Market capitalization | $323.53m |
Enterprise Value | $311.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 38.32 |
P/S ratio (TTM) P/S ratio | 39.84 |
P/B ratio (TTM) P/B ratio | 3.38 |
Revenue (TTM) Revenue | $8.12m |
EBIT (operating result TTM) EBIT | $-169.20m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
5 Analysts have issued a MeiraGTx Holdings plc forecast:
5 Analysts have issued a MeiraGTx Holdings plc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 8.12 8.12 |
81%
81%
|
|
Gross Profit | -5.77 -5.77 |
117%
117%
|
|
EBITDA | -155 -155 |
107%
107%
|
EBIT (Operating Income) EBIT | -169 -169 |
103%
103%
|
Net Profit | -93 -93 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Head office | Cayman Islands |
CEO | Alexandria Forbes |
Employees | 425 |
Founded | 2015 |
Website | www.meiragtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.